Gregory S Calip1, Sruthi Adimadhyam2, Shan Xing2, Julian C Rincon2, Wan-Ju Lee2, Rebekah H Anguiano3. 1. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL 60612; Division of Public Health Sciences, Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: gcalip@uic.edu. 2. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL 60612. 3. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL.
Abstract
OBJECTIVE: Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. METHODS: We conducted a retrospective cohort study of patients aged 18+ years newly initiating etanercept, adalimumab, certolizumab pegol, or golimumab using the Truven Health MarketScan Database between 2009 and 2013. Pharmacy dispensing data were used to calculate 12-month medication possession ratios (MPR) and determine adherence (MPR ≥ 0.80) for up to 3 years after starting therapy. Persistence over each 12-month interval was defined as not having a ≥92-day treatment gap. Multivariable generalized estimating equation models were used to calculate odds ratios (OR) and robust 95% confidence intervals (CI) for associations between patient characteristics and repeated adherence/persistence measures over time. RESULTS: Among 53,477 new users, 14% were young adults (18-34 years), 49% middle-aged (35-54 years), and 37% older adults (55+ years). Overall, 37% of patients were adherent and 83% were persistent in the first year of therapy. The lowest adherence (17%) and persistence (70%) were observed among young adult patients by Year +3. Compared to older adults, middle-aged (OR = 0.73, 95% CI: 0.71-0.76) and young adults (OR = 0.50, 95% CI: 0.47-0.53) were less likely to be adherent. Higher Charlson comorbidity scores, hospitalizations, and emergency department visits were associated with non-adherence/non-persistence. CONCLUSIONS: We observed low adherence to self-administered TNF inhibitors but most patients remained persistent over time. Further efforts to improve adherence in young adults and patients with greater comorbidity are needed.
OBJECTIVE: Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. METHODS: We conducted a retrospective cohort study of patients aged 18+ years newly initiating etanercept, adalimumab, certolizumab pegol, or golimumab using the Truven Health MarketScan Database between 2009 and 2013. Pharmacy dispensing data were used to calculate 12-month medication possession ratios (MPR) and determine adherence (MPR ≥ 0.80) for up to 3 years after starting therapy. Persistence over each 12-month interval was defined as not having a ≥92-day treatment gap. Multivariable generalized estimating equation models were used to calculate odds ratios (OR) and robust 95% confidence intervals (CI) for associations between patient characteristics and repeated adherence/persistence measures over time. RESULTS: Among 53,477 new users, 14% were young adults (18-34 years), 49% middle-aged (35-54 years), and 37% older adults (55+ years). Overall, 37% of patients were adherent and 83% were persistent in the first year of therapy. The lowest adherence (17%) and persistence (70%) were observed among young adult patients by Year +3. Compared to older adults, middle-aged (OR = 0.73, 95% CI: 0.71-0.76) and young adults (OR = 0.50, 95% CI: 0.47-0.53) were less likely to be adherent. Higher Charlson comorbidity scores, hospitalizations, and emergency department visits were associated with non-adherence/non-persistence. CONCLUSIONS: We observed low adherence to self-administered TNF inhibitors but most patients remained persistent over time. Further efforts to improve adherence in young adults and patients with greater comorbidity are needed.
Authors: Michael J Stirratt; Jeffrey R Curtis; Maria I Danila; Richard Hansen; Michael J Miller; C Ann Gakumo Journal: J Gen Intern Med Date: 2018-02 Impact factor: 5.128
Authors: Philip J Mease; Neil A Accortt; Sabrina Rebello; Carol J Etzel; Ryan W Harrison; Girish A Aras; Mahdi M F Gharaibeh; Jeffrey D Greenberg; David H Collier Journal: Rheumatol Int Date: 2019-07-18 Impact factor: 2.631
Authors: Yinzhu Jin; Joan E Landon; Whitney Krueger; Alexander Liede; Rishi J Desai; Seoyoung C Kim Journal: BioDrugs Date: 2022-06-30 Impact factor: 7.744
Authors: Gregory S Calip; Pritesh R Patel; Sruthi Adimadhyam; Shan Xing; Zhaoju Wu; Karen Sweiss; Glen T Schumock; Todd A Lee; Brian C-H Chiu Journal: Int J Cancer Date: 2018-04-16 Impact factor: 7.396
Authors: Manuel Pombo-Suarez; Carlos Sanchez-Piedra; Blanca Garcia-Magallón; Ana Pérez-Gómez; Sara Manrique-Arija; Raquel Martín-Doménech; María Colazo; Cristina Campos; José Campos; Javier Del Pino-Montes; Maria J Arteaga; Luis Cea-Calvo; Federico Díaz-González; Juan J Gómez-Reino Journal: Clin Rheumatol Date: 2021-04-27 Impact factor: 2.980